Cell Source, Inc. (CLCS)
0.90
0.00 (0.00%)
USD |
OTCM |
Feb 06, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 39.12M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 148.3% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.99% |
Profile
| Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. Its Veto Cell immune system management technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY. |
| URL | http://www.cell-source.com |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. Its Veto Cell immune system management technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY. |
| URL | http://www.cell-source.com |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |